- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03284515
Vaccination In Pregnancy Gene Signature: VIP Signature Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Vaccinations are a vital part of ensuring population health, but there is a continued need for new and improved vaccines to be developed and this process of design and development can be both slow and expensive. Vaccination in pregnancy against pathogens such as pertussis, influenza and tetanus is a routine part of antenatal care in many countries. The principle behind this approach is that through vaccination the amount of disease specific antibody is increased in the woman and there is therefore an increase in transplacental transfer to the fetus providing protection for infants after birth. In the UK vaccination against pertussis is recommended from 16 weeks gestation and against influenza at any gestation within the influenza season. There is evidence that pertussis vaccination in pregnancy is highly effective against pertussis in infants too young to be protected by the routine infant immunisation programme (Amirthalingam G et al, 2014, Dabrera G et al, 2015). There is also evidence that this is a safe strategy in pregnancy to protect newborn infants (Donegan K et al, 2014) with no evidence of adverse clinical outcomes for mother or infant.
The BioVacSafe project has been designed to develop techniques which can be used to understand more about biomarkers of safety in individuals' response to vaccines. This will improve our understanding of how reactogenicity can be identified earlier, how adverse reactions can be identified and classified and how individuals interact with vaccines, specifically in conditions of health and disease. Since the start of the BioVacSafe project the importance of vaccination in pregnancy has become better understood and it has become important to include pregnant women as participants in this project. Pregnancy is a time of altered immunity and it may be that there are differences in gene signatures following vaccination in pregnant women compared with non-pregnant women. Insights into this could be extremely important in the development of new vaccines for this population.
Safety of vaccination in pregnancy is of primary importance to pregnant women and their partners, clinical trials investigators, ethics committees, vaccine manufacturers and regulators. Determining specific genetic signatures following vaccination may accelerate vaccine development by predicting possible adverse events early in the development process.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW170RE
- St George's, University of London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant at a gestation of 16-32 weeks
- No contraindications to vaccination according to the green book
- No known immunodeficiency
- Able to understand the details of the study and willing to provide informed consent
Exclusion Criteria:
- Having received a pertussis containing vaccine within the last 12 months
- Contraindications to vaccination according to the green book
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All women
Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
|
Vaccination with a pertussis containing vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gene expression profiles
Time Frame: 24 hours
|
Gene expression profiles in blood samples from pregnant women following vaccination.
|
24 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 17.0060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
Helen Keller InternationalEleanor Crook FoundationNot yet recruitingPregnancy Related | Supplementation | Postnatal Related
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
University of CopenhagenStanford UniversityNot yet recruiting
-
European Vaccine InitiativeKintampo Health Research Centre, Ghana; Groupe de Recherche Action en Sante; Fondation... and other collaboratorsRecruitingPregnancy RelatedBenin, Burkina Faso, Ghana, Malawi
-
Kahramanmaras Sutcu Imam UniversityNot yet recruitingPregnancy RelatedTurkey
-
Fondation Hôpital Saint-JosephRecruiting
-
German Institute of Human NutritionRecruiting
Clinical Trials on Vaccination with a pertussis containing vaccine
-
Universiteit AntwerpenUniversity Hospital, Antwerp; Research Foundation Flanders; Université Libre...Active, not recruiting
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesNot yet recruitingPertussis | Maternal-Fetal Relations | Vaccination; Infection | ImmunoglobulinsBelgium
-
Universiteit AntwerpenChulalongkorn University; Thrasher Research Fund; Institut Pasteur de LilleCompleted
-
St George's, University of LondonThrasher Research Fund; Department of Health, United KingdomUnknownPertussis | Pregnancy Related | Immunization; InfectionUnited Kingdom
-
Chinese University of Hong KongThe University of Hong Kong; Health and Medical Research FundRecruitingQuality of Life | Covid19 | Exercise Capacity | Lung FunctionHong Kong
-
National Institute of Allergy and Infectious Diseases...Istituto Superiore di SanitàCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
-
Karolinska University HospitalKarolinska InstitutetWithdrawnHepatitis B | Hepatitis A | Tuberculosis | Cystic FibrosisSweden
-
Public Health EnglandInstitute of Child Health; St George's, University of LondonCompletedResponses to Infant ImmunisationsUnited Kingdom
-
Public Health EnglandCompletedPertussis | Meningitis | Immunization | Preventive Immunization; MeningitisUnited Kingdom